Introduction {#sec1-1}
============

Focal segmental glomerulosclerosis (FSGS) is the most common cause of adult-onset nephrotic syndrome and accounts for about 20%--25% of cases.\[[@ref1]\] It is hypothesized that podocytic injury in primary FSGS is likely to be immune mediated; therefore, immunosuppressant drugs such as steroids and calcineurin inhibitors (CNI), for example, cyclosporine and tacrolimus are used in its treatment. Although administering steroids is the first line of treatment, approximately 50% of cases turn out to be steroid resistant.\[[@ref2]\] CNI is preferred in the treatment of steroid-resistant FSGS, over other immunosuppressants such as cyclophosphamide and mycophenolate mofetil.\[[@ref3]\] Among CNI, tacrolimus is preferred over cyclosporine because it is a better immunosuppressant and has a lower incidence of nephrotoxicity. However, the remission rate of steroid-resistant FSGS treated with tacrolimus is reported to be 52.2% (complete remission 38.6% and partial remission 13.6%).\[[@ref4]\] The question as to why a subset of patients respond to treatment while the other subset does not is unanswered. In the last few years, the shift of podocyte from its stationary phenotype to migratory phenotype has been documented as a new player in the pathogenesis of FSGS.\[[@ref5]\] Loss of subpodocytic space is a surrogate marker of migratory podocyte phenotype and has not been evaluated in the context of therapy-responsive versus therapy-resistant FSGS. This study was conducted to evaluate electron microscopic features of tacrolimus-responsive versus tacrolimus-resistant adult-onset steroid-resistant CNI-naïve primary FSGS cases.

Materials and Methods {#sec1-2}
=====================

A retrospective study was performed in which steroid-resistant CNI-naïve cases of adult-onset primary FSGS between January 2011 and June 2013 with 60-month follow-up were included in the study. All patients had kidney biopsy before the initiation of tacrolimus, which was subjected to light microscopy, direct immunofluorescence, and electron microscopic studies. Patients having secondary FSGS, collapsing glomerulopathy, interstitial fibrosis tubular atrophy more than 25%, and previous therapy with immunosuppressants other than tacrolimus, for example, cyclophosphamide, mycophenolate mofetil, and azathioprine were excluded from the study.

The study design including treatment received, duration of therapy, and definitions to classify patients into a complete response, partial response, and resistant are highlighted in [Figure 1](#F1){ref-type="fig"}. Nephrotic syndrome was defined by proteinuria ≥3.5 g/day or ≥1.5 g/day along with a serum albumin \<2.5 g/dl, edema, and hyperlipidemia. Tacrolimus resistance was diagnosed in those patients who did not meet the above-mentioned criteria for complete or partial remission at the end of 24 weeks of tacrolimus therapy. Tacrolimus trough levels were estimated using microparticle enzyme-linked immunoassay, Abbott IMx Tacrolimus II assay, Abbott Laboratories, Abbott Park, Ill, USA. A follow-up of 60 weeks was available in all cases (48 weeks of therapy + 12 weeks follow-up).

![The study design including treatment received, duration of therapy, and definitions to classify patients into a complete response, partial response (Tacrolimus responsive), and tacrolimus-resistant groups](IJN-29-90-g001){#F1}

Two electron microscopic grids of each case were examined. Detailed electron microscopic analysis was carried out independently by two nephropathologists (RN and PA) who were blinded with regard to tacrolimus-responsive or tacrolimus-resistant status of patients. About 10--15 electron microscopic photographs of glomeruli were taken in each case. The presence of the following ultrastructural changes in the podocytes was recorded:

Global podocytic foot process effacementActin condensationSwollen secondary podocytic foot processesLoss of subpodocytic spaceVilliform transformation of tertiary podocytic foot processesDilated rough endoplasmic reticulum in podocyte cell bodyMicrocystic change (MC) in podocyte cell body.

Subpodocytic space is defined as the region beneath the podocytic cell body \[[Figure 2c](#F2){ref-type="fig"}\]. The presence or absence of subpodocytic space was evaluated by assessing a minimum of three glomeruli in each case. The loss of sub podocytic space was then graded semiquantitatively on a 4-step scoring scale (no loss of subpodocytic space = 1, loss along 25%--50% glomerular basement membrane length = 2, loss along 50%--75% glomerular basement membrane = 3, and loss along more than 75% glomerular basement membrane = 4). Villiform transformation of tertiary foot processes, prominent rough endoplasmic reticulum, and MC in podocyte cell body are considered as features of podocytic activation and were also semiquantitatively graded on a 4-step scoring scale (0%--25% glomerular area = 1, 26%--50% glomerular area = 2, 51%--75% glomerular area = 3, and \>75% glomerular area = 4). In addition to the above-mentioned parameters, endothelial injury (endothelial cell swelling and loss of fenestration), glomerular basement membrane alteration, immune complex deposits, and tubuloreticular inclusions were looked for.

![(a) Electron microscopic photograph from Case 4 showing podocytic foot process effacement and marked podocytic activation in the form of extensive villiform transformation of tertiary foot processes (Vi), rarefied and bulbous secondary foot processes, prominent rough endoplasmic reticulum, and microcystic change (Uranyl acetate-lead citrate, ×7900). (b) Electron microscopic photograph from Case 14 showing podocytic foot process effacement and podocytic inactivation (Uranyl acetate-lead citrate, ×3950). (c) Electron microscopic photograph showing preserved subpodocytic space (black arrows) in Case 1 (Uranyl acetate-lead citrate, ×12,000). (d) Electron microscopic photograph from Case 11 showing a loss (black star) of subpodocytic space (Uranyl acetate-lead citrate, ×14,000)](IJN-29-90-g002){#F2}

Results {#sec1-3}
=======

Fourteen cases were evaluated in this study and included eleven male patients and three female patients with a mean age of 25.21 years (range 18--43 years). Out of the fourteen cases, seven cases were tacrolimus responsive (includes two cases with partial response) and seven cases were tacrolimus resistant.

Patients responsive to tacrolimus were younger (mean age 19.28 years) as compared to tacrolimus-resistant patients (mean age 31.1 years). The mean duration of illness was greater in tacrolimus-resistant group (10.85 months) as compared to tacrolimus-responsive group (7.7 months). The mean baseline 24 h urinary protein levels were 5.5 g (range: 1.8--19 g) in tacrolimus-responsive group and 4.85 g (range: 2--13.2 g) in tacrolimus-resistant group. The mean baseline estimated glomerular filtration rate (eGFR) was higher in tacrolimus-responsive group (102.8 ml/min) as compared to tacrolimus-resistant group (91.55 ml/min). The salient clinical and laboratory parameters are detailed in Tables [1](#T1){ref-type="table"}--[3](#T3){ref-type="table"}.

###### 

Comparison of salient clinical and laboratory parameters between tacrolimus responsive and tacrolimus resistant cases

                                           All cases (*n*=14)   Tac responsive (*n*=7)   Tac resistant (*n*=7)
  ---------------------------------------- -------------------- ------------------------ -----------------------
  Mean age (years)                         25.21 (18-43)        19.28 (18-23)            31.1 (18-43)
  Sex                                                                                    
  Male                                     11                   6                        5
  Female                                   3                    1                        2
  Mean duration of illness (months)        9.28 (4-38)          7.7 (6-14)               10.85 (4-38)
  Mean baseline 24 h urinary protein (g)   5.17 (1.8-19)        5.5 (1.8-19)             4.85 (2-13.2)
  Mean baseline serum albumin (g/dl)       2.36 (0.6-4.5)       2.31 (1-4.2)             2.41 (0.6-4.5)
  Mean baseline serum creatinine (mg/dl)   0.94 (0.8-1.5)       0.95 (0.8-1.5)           0.92 (0.8-1.1)
  Mean baseline eGFR (ml/min)              97.18 (60.5-124.5)   102.8 (61-124.5)         91.55 (60.5-124.5)
  Mean tacrolimus levels (ng/ml)           6.74 (5.6-9.8)       6.26 (5.6-7)             7.21 (5.7-9.8)

eGFR: Estimated glomerular filtration rate

###### 

Clinical and laboratory details of Tacrolimus responsive patients

  Serial number                        Case 1    Case2       Case 3    Case 4\*   Case 5\*   Case 6    Case 7
  ------------------------------------ --------- ----------- --------- ---------- ---------- --------- ---------
  Age/sex                              19/male   19/female   20/male   18/male    23/male    18/male   18/male
  Duration of illness (months)         7         7           6         6          6          14        8
  Baseline 24 h urinary protein (g)    2.4       1.8         19        4          4          4.9       2.4
  Baseline serum albumin (g/dl)        3         1.1         2.2       4.2        2.3        1         2.4
  Baseline serum creatinine (mg/dl)    0.8       1           0.8       1.5        0.8        0.9       0.9
  Baseline eGFR (ml/min)               124.5     71.4        123       61         120        109.9     109.9
  Tacrolimus levels (ng/ml)            6.98      6.4         6.1       5.9        5.9        7         5.6
  3 months 24 h urinary protein (g)    0.3       2.3         1.4       0.8        4.2        3.9       0.27
  3 months serum albumin (g/dl)        4.5       4           3.5       4.9        4          2.2       3.9
  3 months serum creatinine (mg/dl)    1.2       0.6         1.2       1.3        0.7        0.9       0.8
  6 months 24 h urinary protein (g)    0.3       0.2         0.3       0.6        3.4        2.1       0.27
  6 months serum albumin (g/dl)        4.5       4.1         3.5       4.1        3.6        3.7       3.8
  6 months serum creatinine (mg/dl)    1.2       0.7         1         1.4        0.8        0.9       0.9
  6 months eGFR (ml/min)               78        107.8       95.3      66         120        109.9     109.9
  9 months 24 h urinary protein (g)    0.3       0.2         0.3       0.6        0.8        1.2       0.3
  9 months serum albumin (g/dl)        3.97      4           3.7       4.1        3.8        4.1       3.6
  9 months serum creatinine (mg/dl)    1         0.7         1         1.5        0.8        0.9       0.8
  12 months 24 h urinary protein (g)   0.3       0.2         0.3       0.7        1.1        0.3       0.3
  12 months serum albumin (g/dl)       4         3.8         3.8       4.2        3.8        4.3       3.6
  12 months serum creatinine (mg/dl)   1         0.8         1.1       1.5        0.8        1.1       0.8
  12 months eGFR (ml/min)              95.3      91.4        84.5      60.3       119        86.2      124.5
  Time to response (months)            3         3           3         3          6          6         3
  Relapse status (yes/no)              No        Yes         No        Yes        No         No        No

\*Partial response. eGFR: Estimated glomerular filtration rate

###### 

Clinical and laboratory details of Tacrolimus resistant patients

  Serial number                       Case 8    Case 9      Case 10   Case 11   Case 12   Case 13     Case 14
  ----------------------------------- --------- ----------- --------- --------- --------- ----------- ---------
  Age/sex                             40/male   18/female   22/male   38/male   19/male   43/female   38/male
  Duration of illness (months)        8         6           10        6         4         4           38
  Baseline 24 h urinary protein (g)   2.4       4.2         4.1       2         2.9       5.2         13.2
  Baseline serum albumin (g/dl)       2.3       1.9         3.8       0.6       1.6       4.5         2.2
  Baseline serum creatinine (mg/dl)   0.9       1           0.8       1.1       0.8       1           0.9
  Baseline eGFR (ml/min)              93.5      72.2        120.9     74.9      124.5     60.5        94.4
  Tacrolimus levels (ng/ml)           6.2       7.2         7.2       7.2       5.7       9.8         7.2
  3 months 24 h urinary protein (g)   1.8       4           2.7       1.9       2         3           9.3
  3 months serum albumin (g/dl)       2.8       2.2         2.3       2.6       2.9       3.3         2.3
  3 months serum creatinine (mg/dl)   1.1       0.9         0.7       1.7       0.8       3.4         1
  6 months 24 h urinary protein (g)   4.4       3           1.4       5.7       3.2       3.2         13.3
  6 months serum albumin (g/dl)       2         2           1.7       3.3       1.1       2.2         2.2
  6 months serum creatinine (mg/dl)   1.5       1           0.8       2.2       2.7       1.2         1
  6 months eGFR (ml/min)              51.8      72.2        120.9     33.7      30.6      49          83.6

With regard to electron microscopic features, global podocytic foot process effacement, actin condensation, and rarefied and bulbous secondary foot processes (SFP) were noted in all 14 cases. Out of seven tacrolimus-responsive cases, five cases showed ultrastructural features of podocytic activation (villiform transformation of tertiary foot processes and/or prominent rough endoplasmic reticulum and/or MC) affecting most of the podocytes \[Grade 4, [Figure 2a](#F2){ref-type="fig"}\]. Out of seven tacrolimus-resistant cases, only two cases showed features of podocytic activation, while the remaining five cases showed features of podocytic inactivation \[Grade 1, [Figure 2b](#F2){ref-type="fig"}\].

Extensive (Grade 4) subpodocytic space loss was observed in five tacrolimus-resistant cases \[[Figure 2d](#F2){ref-type="fig"}\], both the cases showing a partial response to tacrolimus and only one tacrolimus-responsive case. The detailed ultrastructural features of tacrolimus-responsive and tacrolimus-resistant cases are tabulated in Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}, respectively.

###### 

Ultrastructural features of tacrolimus-responsive cases

  Features                                              Case 1   Case 2   Case 3   Case 4\*   Case 5\*   Case 6   Case 7
  ----------------------------------------------------- -------- -------- -------- ---------- ---------- -------- --------
  Foot process effacement                               \+       \+       \+       \+         \+         \+       \+
  Actin condensation                                    \+       \+       \+       \+         \+         \+       \+
  Swollen secondary foot processes                      \+       \+       \+       \+         \+         \+       \+
  Subpodocytic space loss                               Nil      Nil      Nil      4          4          4        Nil
  Villiform transformation of tertiary foot processes   4        1        3        4          4          4        1
  Rough endoplasmic reticulum                           4        1        2        2          3          2        1
  Microcystic change                                    3        1        2        2          4          2        1

\*Partial response

###### 

Ultrastructural features of Tacrolimus resistant cases

  Features                                              Case 8   Case 9   Case 10   Case 11   Case 12   Case 13   Case 14
  ----------------------------------------------------- -------- -------- --------- --------- --------- --------- ---------
  Foot process effacement                               \+       \+       \+        \+        \+        \+        \+
  Actin condensation                                    \+       \+       \+        \+        \+        \+        \+
  Swollen secondary foot processes                      \+       \+       \+        \+        \+        \+        \+
  Sub-podocytic space loss                              4        1        4         4         4         1         4
  Villiform transformation of tertiary foot processes   1        1        1         4         2         4         1
  Rough endoplasmic reticulum                           1        2        1         3         1         3         1
  Microcystic change                                    2        1        1         2         1         3         1

Discussion {#sec1-4}
==========

Before 2009, the glomerular filtration barrier comprised of three layers, namely, fenestrated glomerular endothelium, glomerular basement membrane, and slit diaphragm. In 2009, two additional layers were described, i.e., endothelial surface layer and subpodocytic space. While the endothelial surface layer determines permeability, the subpodocytic space plays an important role in ultrafiltration and hydraulic resistance.\[[@ref6]\]

The mechanisms of injury causing primary FSGS are poorly understood. The theory of immune dysregulation leading to podocytopathy is acceptable till date, and invariably all cases are treated with immune modulatory agents. Ongoing research in the present decade highlights various other pathogenetic mechanisms such as a change in podocytic phenotype. In health, the podocytes are in a stationary phenotype while they acquire a migratory phenotype under stress. This podocytic phenotypic change is brought about by Rho-GTPase mediated regulation of actin cytoskeleton of podocytes.\[[@ref5]\] The other molecules implicated in inducing migratory podocytic phenotype are protein tyrosine phosphatase 1B, Sphingomyelinase-like phosphodiesterase 3b, angiotensin II, and monocyte chemoattractant protein-1.\[[@ref7][@ref8][@ref9][@ref10]\]

In the present study, global podocyte foot process effacement, actin condensation, and swollen SFP were noted in all 14 cases. The subpodocytic space was preserved in four out of the five Tacrolimus-responsive cases and lost in both the cases with partial response and five out of the seven cases with tacrolimus resistance. Loss of subpodocytic space is a surrogate marker of migratory phenotype of podocyte. Therefore, almost all cases with this ultrastructural feature fared worse (resistant or partial response to Tacrolimus), except one tacrolimus-responsive case. Ultrastructural features of podocytic activation were conspicuous in tacrolimus-responsive patients, indicating early podocytic response to injury and attempts at regeneration.

Conclusion {#sec1-5}
==========

In the present study, we have compared podocytic activation and presence or absence of subpodocytic space in tacrolimus-responsive versus tacrolimus-resistant cases to identify potential electron microscopic features predictive of response to treatment, of which loss of subpodocytic space indicating migratory phenotype is the most important and consistent feature.
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